Instructions for Artoxan (Tenoxicam) 20 mg 3 ampoules
English product name
Artoxan
Release form
Lyophilizate for preparation of solution for injection in/in and in/m
Description
Lyophilizate for preparation of solution for injection into/into/into/out - lyophilized powder or compacted mass in the form of green-yellow tablet; solvent - colorless transparent liquid without smell.
1 fl
Tenoxicam 20 mg
Auxiliary substances:
Mannitol - 80 mg, ascorbic acid - 0.4 mg, Dehydrate edetate - 0.2 mg, tromethamol - 3.3 mg, sodium hydroxide and chlorohydrogen acid - Q.S.
Solvent composition (1 amp): water d/i - 2 ml.
Colorless glass bottles (3) with solvent (amp. 2 ml 3 pcs.) - packages of cell contour (1) - packs of cardboard.
ATC codes Artoxan
M01AC02 Tenoxicam
Clinical-pharmacological groups / Group affiliation
NAPS
Active substance
Tenoxicam
Pharmacotherapy group Artoxan:
NSAIDs
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C. Do not freeze.
Best before date Artoxan
Lyophilizate shelf life - 3 years, solvent - 4 years
Testimony Artoxan:
- rheumatoid arthritis;
- osteoarthritis;
- ankylosing spondylitis;
- joint syndrome in aggravation of gout;
- bursitis;
- tendovaginite;
- pain syndrome (mild to moderate intensity):
- arthralgia,
- myalgia,
- neuralgia,
- migraine,
- toothache and headache,
- algodismenorrhea;
- pain in injuries,
- burns.
- The drug is intended for symptomatic therapy, reducing pain and inflammation at the time of use,
- the progression of the disease does not affect.
Method of use, course and dosage Artoxan:
For b/m or b/b introduction.
B/m or b/v is used for short-term (one to two days) treatment at a dose of 20 mg once a day. If further therapy is necessary, oral medicinal forms of Tenoxicam are converted.
The solution for injection is prepared immediately prior to use by dissolving the contents of the bottle with the supplied solvent. After cooking, the needle is replaced.
B/m injections are done deeply.
The duration of the In/In introduction must not be less than fifteen seconds.
Pharmacological effect:
Tenoxicam is a thienotiazine derivative of oxycamus, which is a NSAIDs. In addition to anti-inflammatory, analgesic and antipyretic action, the drug also prevents the aggregation of platelets. The mechanism of action is based on the suppression of the activity of the isoenzymes COX-1 and COX-2, as a result of which prostaglandin synthesis in the site of inflammation, as well as in other tissues of the body, is reduced. In addition, Tenoxicam reduces the accumulation of leukocytes in the inflammation site, reduces the activity of proteoglykanase and collagenase in human cartilage.
Anti-inflammatory action develops towards the end of the first week of therapy.
Application for kidney disorders
With caution: chronic kidney failure (CC 30-60 ml/min).
Use in liver disorders
With caution: liver disease in anamnesis, hepatic porphyria.
Terms of Sale
The drug is prescription.
- Nosology (ICD codes)
- G43
- Migraine
- K08.8
- Other refined changes of teeth and their support apparatus (including toothache)
- M05
- Seropositive rheumatoid arthritis
- M10
- Podagra
- M15
- Polyarthrosis
- M19.9
- Arthrosis unspecified
- M25.5
- Joint pain
- M42
- Spinal osteochondrosis
- M45
- Ankylosing spondylitis
- M47
- Spondylosis
- M65
- Synovitis and tenosinovites
- M70
- Soft tissue diseases related to load, overload and pressure
- M71
- Other bursopathy
- M79.1
- Mialgia
- M79.2
- Neuralgia and Neuritis Unspecified
- N94.4
- Primary dysmenorrhea
- N94.5
- Secondary dysmenorrhea
- R51
- Headache
- R52.0
- Acute pain
- R52.2
- Other persistent pain (chronic)
- T14.3
- Dislocation, stretching and overtension of the capsule-bonding apparatus of the unspecified body region joint
- T14.9
- Injury unspecified
- T30
- Thermal and chemical burns of unspecified location
